These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 16447801

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
    Wu BY, Guo KY, Song CY, Yang, Li D.
    Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
    [Abstract] [Full Text] [Related]

  • 24. [Non-myeloablative/reduced-intensity hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Kanda Y, Mineishi S.
    Nihon Rinsho; 2001 Dec; 59(12):2427-32. PubMed ID: 11766351
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S.
    Blood Cells Mol Dis; 2008 Dec; 40(1):48-54. PubMed ID: 17827036
    [Abstract] [Full Text] [Related]

  • 27. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.
    Das M, Saikia TK, Advani SH, Parikh PM, Tawde S.
    Bone Marrow Transplant; 2003 Jul; 32(2):125-9. PubMed ID: 12838275
    [Abstract] [Full Text] [Related]

  • 28. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y.
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [Abstract] [Full Text] [Related]

  • 29. [Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].
    Ichinohe T, Ishikawa T.
    Nihon Rinsho; 2003 Sep; 61(9):1573-8. PubMed ID: 14515726
    [Abstract] [Full Text] [Related]

  • 30. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 33. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.
    Qazilbash MH, Giralt SA, Champlin RE.
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D, Sedzimirska M, Lange A.
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
    Massenkeil G, Nagy M, Lawang M, Rosen O, Genvresse I, Geserick G, Dörken B, Arnold R.
    Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.